Capricor Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · San Diego, CA
CAPR chart
What traders are saying about $CAPR
Latest postsCapricor Therapeutics, Inc. news
- CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision
stocktwits.com ·
- Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology
Yahoo Finance ·
- In patients with Duchenne and heart disease, heart function was 2.8 percentage points higher than placebo.
Stock Titan ·
- Capricor Therapeutics Stock Price Forecast. Should You Buy CAPR?
StockInvest.us ·
- Capricor Therapeutics Faces FDA Approval Uncertainty as CAPR Sto
GuruFocus ·
- What Sits Behind the 31.93% Weekly Gain at Capricor Therapeutics (NASDAQ:CAPR)?
kalkine.ca ·
- Why Did Silence Therapeutics (NASDAQ:SLN) Climb 95.21% in a Month While Lyell Immunopharma (NASDAQ:LYEL), Teladoc Health (NYSE:TDOC), Jin Medical International (NASDAQ:ZJYL) and Capricor Therapeutics (NASDAQ:CAPR) Also Gained?
kalkine.ca ·
- Capricor Therapeutics, Inc. (4LN2.F) Seasonal Returns Chart - Yahoo Finance
Yahoo! Finance Canada ·
- When Will the FDA Act on Capricor Therapeutics (NASDAQ:CAPR) After a 3 to 9 Panel Vote?
kalkine.ca ·
- Why Did a USD 40.8 Million Warrant Gain Narrow the Net Loss at Compass Pathways (NASDAQ:CMPS), as Enovis (NYSE:ENOV), QuidelOrtho (NASDAQ:QDEL) and Capricor Therapeutics (NASDAQ:CAPR) Carry Mixed Signals?
kalkine.ca ·
- Capricor Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27, Implies 228% Upside
TradingView ·
- CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel
stocktwits.com ·
Capricor Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $22.3M | $25.2M | $2.6M |
| Net income | -$105.0M | -$40.5M | -$22.3M | -$29.0M |
| Diluted EPS | $-2.26 | $-1.15 | $-0.83 | $-1.18 |
| Total assets (year end) | $355.9M | $170.5M | $58.7M | $50.1M |
| Cash and equivalents (year end) | $287.8M | $11.3M | $14.7M | $9.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Capricor Therapeutics, Inc.
- Ticker
- CAPR (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1133869
- Former names
- Nile Therapeutics, Inc., SMI PRODUCTS INC
Frequently asked questions
What exchange is Capricor Therapeutics, Inc. listed on?
Capricor Therapeutics, Inc. trades on the Nasdaq under the ticker symbol CAPR.
What industry is Capricor Therapeutics, Inc. in?
Capricor Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Capricor Therapeutics, Inc. headquartered?
Capricor Therapeutics, Inc.'s business address on file with the SEC is in San Diego, CA.
When does Capricor Therapeutics, Inc.'s fiscal year end?
Capricor Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Capricor Therapeutics, Inc. report?
Capricor Therapeutics, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.